SDC1 and triple-negative breast carcinoma: Another study showed that targeting SDC1/CD138 by employing immuno-PET imaging and radioimmunotherapy (RIT) using the radiolabeled antihuman SDC1 B-B4 significantly induced tumor regression in a xenograft model of triple-negative breast cancer [160].